Dealing with Multiple Endpoints

Current Problems in Cancer

Volumn 30, Issue 6, 2006, Pages 298-306

  Dueck, Amylou ^a   Novotny, Paul J ^a   Sloan, Jeff A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; CYTARABINE; IMATINIB; LUBRICATING AGENT; PLACEBO; REPLENS; UNCLASSIFIED DRUG; VENLAFAXINE;

ANOREXIA; ARTICLE; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; HOT FLUSH; HUMAN; MEDICAL RESEARCH; QUALITY OF LIFE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VAGINA PAIN; VAGINAL DRYNESS; VAGINAL PRURITUS;

CLINICAL TRIALS; ENDPOINT DETERMINATION; HUMANS; KARNOFSKY PERFORMANCE STATUS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 33751110512     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2006.08.007     Document Type: Article

References (13)

1. Loprinzi C.L., Abu-Ghazaleh S., Sloan J.A., van Haelst-Pisani C., Hammer A.M., Rowland Jr. K.M., et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 15 (1997) 969-973
2. Rummans T.A., Clark M.M., Sloan J.A., Frost M.H., Bostwick J.M., Atherton P.J., et al. Impacting quality of life for patients with advanced cancer with a structured multi-disciplinary intervention: a randomized controlled trial. J Clin Oncol 24 (2006) 635-642
3. Hahn E.A., Glendenning G.A., Sorensen M.V., Hudgens S.A., Druker B.J., Guilhot F., et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21 (2003) 2138-2146
4. Bacik J., Mazumdar M., Murphy B.A., Fairclough D.L., Eremenco S., Mariani T., et al. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res 13 (2004) 137-154
5. Brooks R. EuroQol: the current state of play. Health Policy 37 (1996) 53-72
6. Loprinzi C.L., Kugler J.W., Sloan J.A., Mailliard J.A., LaVasseur B.I., Barton D.L., et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 356 (2000) 2059-2063
7. Barton D., La Vasseur B., Loprinzi C., Novotny P.J., Wilwerding M.B., and Sloan J.A. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum 29 (2002) 33-40
8. Bender R., and Lange S. Adjusting for multiple testing: when and how?. J Clin Epidemiol 54 (2001) 343-349
9. O'Brien P.C. Procedures for comparing samples with multiple endpoints. Biometrics 40 (1984) 1079-1087
10. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
11. Fairclough D.L. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med 16 (1997) 1197-1209
12. Sloan J.A., Loprinzi C.L., Laurine J.A., Novotny P.J., Vargas-Chanes D., Krook J.E., et al. A simple stratification factor prognostic for survival in advanced cancer: the Good/Bad/Uncertain Index. J Clin Oncol 19 (2001) 3539-3546
13. Cleeland C.S., and Ryan K.M. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23 (1994) 129-138